Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk Progression 60% Time to viral- 9% primary Time to viral- (b) 9% primary Favipiravir  FIGHT-COVID-19  LATE TREATMENT  RCT Is late treatment with favipiravir + combined treatments beneficial for COVID-19? RCT 200 patients in Thailand (August 2020 - August 2021) Trial compares with oseltamivir, results vs. placebo may differ Lower progression with favipiravir + combined treatments (p=0.0085) c19early.org Atipornwanich et al., SSRN Electronic J., Oct 2021 Favors favipiravir Favors oseltamivir

Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)

Atipornwanich et al., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, FIGHT-COVID-19, NCT04303299
Oct 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 200 moderate/severe patients in Thailand, showing significantly lower progression with favipiravir vs. oseltamivir. NCT04303299 (history).
Study covers favipiravir and HCQ.
risk of death, 23.1% lower, RR 0.77, p = 0.66, treatment 10 of 100 (10.0%), control 13 of 100 (13.0%), NNT 33, favipiravir arms vs. oseltamivir arms.
risk of progression, 60.0% lower, RR 0.40, p = 0.009, treatment 10 of 100 (10.0%), control 25 of 100 (25.0%), NNT 6.7, favipiravir arms vs. oseltamivir arms.
time to viral-, 8.7% lower, relative time 0.91, p = 0.43, treatment mean 9.5 (±5.0) n=50, control mean 10.4 (±6.3) n=50, HCQ arms, primary outcome.
time to viral-, 8.9% lower, relative time 0.91, p = 0.34, treatment mean 10.2 (±4.6) n=50, control mean 11.2 (±5.7) n=50, non-HCQ arms, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Atipornwanich et al., 5 Oct 2021, Randomized Controlled Trial, Thailand, peer-reviewed, 16 authors, study period 19 August, 2020 - 28 August, 2021, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with lopinavir/ritonavir or duranivir/ritonavir/HCQ) - results of individual treatments may vary, trial NCT04303299 (history) (FIGHT-COVID-19).
This PaperFavipiravirAll
M.D Kriangsak Atipornwanich, Associate Professor Subsai Kongsaengdao, M.D Piyathida Harnsomburana, M.D Rienthong Nanna, M.D Chatchawan Chtuparisute, M.D Piamlarp Saengsayan, M.D Kittima Bangpattanasiri, M.D Weerawat Manosuthi, M.D Narumol Sawanpanyalert, M.D Attasit Srisubat, M.D Somchai Thanasithichai, M.D Benchalak Maneeton, M.D Narong Maneeton, Chuthamanee Suthisisang, PhD B Pharm, Jaturong Pratuangdejkul, M.D Somsak Akksilp, Professor Dusit Sujurarat, Hospital Rajavithi, Bangkok Bangkok, Thailand
Various combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, high-dose Oseltamivir, and Hydroxychloroquine for the treatment of Covid-19: A randomized controlled trial. (FIGHT-COVID-19 Study)
References
Hata, Koseki, Yamaguchi, Limited inhibitory effects of Oseltamivir and zanamivir on human sialidases, Antimicrob Agents Chemother, doi:10.1128/AAC.00344-08
Hung, Lung, Tso, Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with Covid -19: an open-label, randomised, phase 2 trial, Lancet, doi:10.1016/S0140-6736(20)31042-4
Kriangsak, Akksilp, Sawanpanyalert, Srisubat, Thanasithichai et al., Various Combination of Antiviral Treatment of Covid -19 Pneumonia
Shinkai, Tsushima, Tanaka, A Randomized, Phase III Clinical Trial, Infect Dis Ther, doi:10.1007/s40121-021-00517-4
Wang, Zhang, Du, Remdesivir in adults with severe Covid -19: a randomised, doubleblind, placebo-controlled, multicentre trial [published correction appears in, Lancet
{ 'DOI': '10.2139/ssrn.3936499', 'ISSN': ['1556-5068'], 'URL': 'http://dx.doi.org/10.2139/ssrn.3936499', 'author': [ {'affiliation': [], 'family': 'Atipornwanich', 'given': 'Kriangsak', 'sequence': 'first'}, {'affiliation': [], 'family': 'Kongsaengdao', 'given': 'Subsai', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Harnsomburana', 'given': 'Piyathida', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Nanna', 'given': 'Rienthong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chtuparisute', 'given': 'Chatchawan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Saengsayan', 'given': 'Piamlarp', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bangpattanasiri', 'given': 'Kittima', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Manosuthi', 'given': 'Weerawat', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sawanpanyalert', 'given': 'Narumol', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Srisubat', 'given': 'Attasit', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Thanasithichai', 'given': 'Somchai', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Maneeton', 'given': 'Benchalak', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Maneeton', 'given': 'Narong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Suthisisang', 'given': 'Chuthamanee', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pratuangdejkul', 'given': 'Jaturong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Akksilp', 'given': 'Somsak', 'sequence': 'additional'}], 'container-title': ['SSRN Electronic Journal'], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2021, 10, 10]], 'date-time': '2021-10-10T12:55:10Z', 'timestamp': 1633870510000}, 'deposited': { 'date-parts': [[2021, 10, 10]], 'date-time': '2021-10-10T12:55:13Z', 'timestamp': 1633870513000}, 'indexed': {'date-parts': [[2022, 1, 10]], 'date-time': '2022-01-10T12:29:11Z', 'timestamp': 1641817751857}, 'is-referenced-by-count': 1, 'issn-type': [{'type': 'electronic', 'value': '1556-5068'}], 'issued': {'date-parts': [[2021]]}, 'language': 'en', 'member': '78', 'original-title': [], 'prefix': '10.2139', 'published': {'date-parts': [[2021]]}, 'published-other': {'date-parts': [[2021]]}, 'publisher': 'Elsevier BV', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'score': 1, 'short-container-title': ['SSRN Journal'], 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'title': [ 'Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose ' 'Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled ' 'Trial (FIGHT-COVID-19 Study)'], 'type': 'journal-article'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit